Results 111 to 120 of about 1,097,021 (302)
Prospects for combining immune checkpoint blockade with PARP inhibition
The immunogenicity of a cancer cell is derived from accumulated somatic mutations. However, on the contrary to increased immunogenicity, anti-cancer immune response tends to be feeble.
Anping Li +5 more
doaj +1 more source
Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley +1 more source
BackgroundThe role of upfront cytoreductive nephrectomy remains debatable in the present era of tyrosine kinase inhibitors and immune checkpoint inhibitors.
Gu-Shun Lai +8 more
doaj +1 more source
The multifaceted roles of lysosomes in cancer
Lysosomes support cancer cell adaptation by integrating macromolecule degradation and nutrient recycling with nutrient sensing, inter‐organelle communication and immune regulation. These interconnected functions can promote tumour growth, stress tolerance and therapy resistance, while also creating context‐dependent vulnerabilities that may be ...
Jia Li, Kevin M. Ryan
wiley +1 more source
Vascular normalization confers an endothelial immune suppressive gene expression profile
We compare the immunoregulatory gene expression profiles of healthy endothelial cells or endothelial cells from tumors having a normalized endothelium (low leakage) with that of wild‐type tumors (high leakage) and observe that the wild‐type tumor endothelium exhibits immunostimulatory properties.
Liqun He, Michael Welsh
wiley +1 more source
The landscape of checkpoint inhibitors in oncology
Immune checkpoint inhibitor (ICI) therapies have become increasingly popular treatment options for patients with cancer, even for patients in non-metastatic settings. Survival and responses have been reported for individual tumor types, but little is known about these outcomes, collectively. We sought to provide an overview of overall survival (OS) and
Haslam, Alyson +3 more
openaire +4 more sources
Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents [PDF]
Markus Joerger,1 Kira-Lee Koster,1 Tomas Janik,2 Floris A de Jong3,4 1Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; 2Research & Development Department, Mundipharma Research Limited, Cambridge, UK ...
de Jong FA +3 more
core
Cardiotoxicity of immune checkpoint inhibitors [PDF]
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity.
Gilda Varricchi +15 more
core +1 more source
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis +20 more
wiley +1 more source
Enterotoxigenic Bacteroides fragilis is a gut bacterium linked to bowel cancer. We propose that its toxin acts along two routes: at the cell surface, cutting the adhesion protein E‐cadherin and triggering inflammation; and inside the cell, delivered by bacterial vesicles, switching on NOD1 and cancer stem cell programs.
Kangchan Choi +2 more
wiley +1 more source

